English 中文简体 中文繁体

Alphamab Oncology Initiates Phase II Clinical Trial of KN046 in Patients with Advanced Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

May 20, 2019 15:00 Eastern Daylight Time

SUZHOU, China, May 20, 2019 - A phase II clinical trial to evaluate the efficacy, safety and tolerability of KN046 in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma was successfully initiated by Alphamab Oncology at the Fifth Medical Center of PLA General Hospital today, the 15th International Clinical Trials Day.

KN046 is the world's first recombinant humanized PD-L1/CTLA-4 bispecific antibody independently developed by Alphamab Oncology. It simultaneously targets two important immunomodulatory targets that have been commercially validated, and relieves the inhibition of tumor-specific lymphocytes at two different types of immune regulation, thus activating T cells more effectively and enhancing the immunity against tumors. Preliminary results of phase I clinical trials conducted in Australia and China for KN046 have demonstrated potential promising efficacy and safety.

The phase II clinical trial will be conducted in five clinical sites, including the Fifth Medical Center of PLA General Hospital, Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, the First Affiliated Hospital of Zhengzhou University, the Tumor Hospital Affiliated to Harbin Medical University and the First Affiliated Hospital of Zhejiang University School of Medicine. It is expected to enroll 30 patients.

Professor Jianming Xu, director of the Gastrointestinal Cancer Center in the Fifth Medical Center of PLA General Hospital, commented: “When conducting clinical trials, we will abide by laws and regulations, ethical principles and scientific principles to maximize the benefit to the patients. Our hospital will lead other sites to complete this trial following scientific and ethical principles."

All the five clinical sites have strong capabilities in treating gastrointestinal cancers, and researchers participated in this trial have received systematic training and obtained relevant qualifications, and have very clear objectives and full confidence in the study of KN046-204.

About Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in China dedicated to the development of innovative biologics for cancer therapy globally. Thus far, four drug candidates in Alphamab Oncology's pipeline have advanced into clinical development phase. With multiple in-house proprietary platforms for innovative biopharmaceuticals, Alphamab Oncology has built a robust pipeline in oncology and immunology to benefit cancer patients around the world.

Visit http://www.alphamabonc.com for more information.


Contacts:
Alphamab Oncology
Fengzhang Guan, +86-512-62850800 Extension 8807
fengzhangguan@alphamabonc.com